October 23, 2013 By CPhI.cn

Recently, the 17th Beijing International Biopharmaceutical Industry Development Forum claimed that Beijing's launching the "Beijing biomedical industry leaping development project" in 2010 (the G20 program) had promoted the industry to transfer from the "small, scattered, weak" to "high. Cohesive, strength ", which brought about an increase in size of Beijing biomedical industry from less than 40 billion yuan in 2009 to102.3 billion yuan in 2012.

According to Zhu Shilong, deputy director of Beijing Municipal Science and Technology Commission, in 2015, the total revenue of Beijing bio-pharmaceutical industry will exceed 180 billion yuan. Moreover, it will become a globally influential biomedical innovation center, with high-end product manufacturing, and talent and excellent enterprise gathering.

The theme of this forum was " opportunities of cross-border integration, new development for biomedicine", focusing on innovation on the era of big data information, electronics, new materials and pharmaceutical industry, as well as China, Japan and South Korea's cooperation and innovation, innovation of finance and technology and innovation of government research cooperation mechanism. It aimed to jointly plan for industry trends and direction of development in the next three years, pushing Beijing biomedical field "technology integration model cross."